Alpha Cognition Inc. Common Stock ACOG
8.15 USD -0.38 (-4.45%)
At closeNov 5, 2026, 4:00 PM EST
8.15 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
8.11 Day range 8.56
4.50 52-week range 9.75
- YTD
- +25.38%
- 1 year
- +38.61%
- Market cap
- 177.49M
- EPS (ttm)
- -1.32
- YTD return
- +25.38%
- 1-year return
- +38.61%
- Volume
- 60.19K
- Avg volume
- 123.24K
- Open
- 8.48
- Previous close
- 8.53
- Day's range
- 8.11 – 8.56
- 52-week range
- 4.50 – 9.75
YTD +1.65 (+25.38%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 5.66
- 200-day average
- 5.66
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ACOG Revenue — quarterly 6.09M
ACOG Net income — quarterly -8.79M
ACOG EPS — quarterly -0.40
News
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update 
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® 
Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages 
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress 
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine 
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care 
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI) 
Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00 
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Your note
Sign in to keep a note on ACOG — it syncs with the Stock Master app.